

Electronic Supporting Information

Leveraging kinase inhibitors to develop small molecule tools for imaging kinases by fluorescence microscopy

Authors: Zijuan Zhang, Nicholas Kwiatkowski, Hong Zeng, Sang Min Lim, Nathanael S. Gray, Wei Zhang, and Priscilla L. Yang

Materials and Methods

Synthesis of Mps1-IN-BODIPY The synthesis of Mps1-IN-BODIPY was adapted from the synthesis of parent compound, Mps1-IN-1.¹ The chlorine in compound **1** was displaced with *tert*-butyl 4-(1-(4-amino-3-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylate to give **2**. ¹H NMR (300 MHz, CDCl₃): δ 8.33 (s, 1H), 8.23 (d, *J* = 8.4 Hz, 1H), 7.87 (d, *J* = 7.5 Hz, 1H), 7.55 (m, 2H), 7.10 (t, *J* = 7.8 Hz, 1H), 6.98 (d, *J* = 3.6 Hz, 1H), 6.71 (s, 1H), 6.57 (s, 1H), 6.39 (s, 1H), 6.27 (d, *J* = 3.6 Hz, 1H), 5.59 (s, 2H), 4.28-4.04 (b, 2H), 3.88 (s, 3H), 3.62 (t, *J* = 8.1 Hz, 2H), 3.31 (m, *J* = 6.9 Hz, 1H), 3.17 (b, 4H), 2.76 (b, 4H), 2.70 (b, 2H), 2.45 (tt, 1H), 1.86 (bd, *J* = 10.8 Hz, 2H), 1.46 (s, 9H), 1.44 (b, 2H), 1.28 (d, *J* = 6.9 Hz, 6H), 0.95 (t, *J* = 8.1 Hz, 2H), -0.07 (s, 9H); ¹³C NMR (300 MHz, CDCl₃): δ 154.6, 153.2, 149.1, 148.5, 146.2, 142.2, 141.6, 134.7, 131.6, 124.5, 123.5, 122.6, 121.0, 120.0, 119.1, 108.4, 104.8, 101.0, 98.7, 90.1, 79.5, 72.9, 71.9, 66.1, 61.9, 55.6, 54.5, 50.9, 49.2, 28.6, 28.5, 17.8, 15.4, -1.3; (*m/z*): [M+1] 834.3. Deprotection to remove the BOC and SEM groups of compound **2** followed by amide coupling with BODIPY acid produced the target Mps1-IN-BODIPY. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.11 (s, 1H), 8.43 (s, 1H), 8.20 (d, *J* = 8.8 Hz, 1H), 7.78 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.67 (m, 3H), 7.56 (s, 1H), 7.19 (t, *J* = 7.2 Hz, 1H), 7.08 (d, *J* = 4.0 Hz, 1H), 6.92 (dd, *J* = 3.2, 2.4 Hz, 1H), 6.59 (s, 2H), 6.41 (d, *J* = 4.0 Hz, 2H), 6.28 (s, 1H), 6.05 (dd, *J* = 3.2, 2.0 Hz, 1H), 4.41 (m, 1H), 3.91 (m, 1H), 3.79 (s, 3H), 3.38 (m, *J* = 7.2 Hz, 1H), 3.06 (m, 5H), 2.98 (t, *J* = 12.0 Hz, 2H), 2.72 (q, *J* = 6.8 Hz, 2H), 2.61 (b, 5H), 2.45 (s, 3H),

2.24 (s, 3 H), 1.79 (b, 2 H), 1.21 (s, 1 H), 1.14 (d, $J = 6.8$ Hz, 6H); HRMS ESI calculated for $C_{46}H_{55}BF_2N_9O_4S$ $[M+H]^+$ 878.4159; found 878.4157.

Synthesis of BI-BODIPY The synthesis of BI-BODIPY was adapted from the synthesis of parent compound, BI2536.² Amide coupling of **3** with *t*-butyl 4-((1*R*,4*R*)-4-aminocyclohexyl)piperazine-1-carboxylate afforded compound **4**. Deprotection of compound **4** followed by amide coupling with BODIPY acid produced the target BI-BODIPY. ¹H NMR (400 MHz, CD₃OD) δ 8.47 – 8.39 (m, 1H), 7.66 (s, 1H), 7.42–7.31 (m, 3H), 6.91 (d, $J = 4.0$ Hz, 1H), 6.23 (d, $J = 4.0$ Hz, 1H), 6.12 (s, 1H), 4.70–4.52 (m, 2H), 4.23 (dd, $J = 7.6, 3.4$ Hz, 1H), 4.10–3.91 (m, 2H), 3.90 (s, 3H), 3.71 (d, $J = 3.7$ Hz, 2H), 3.50 (d, $J = 3.9$ Hz, 2H), 3.45–3.36 (m, 2H), 3.11 (t, $J = 7.6$ Hz, 2H), 2.76–2.65 (m, 2H), 2.47 (dd, $J = 11.9, 6.8$ Hz, 2H), 2.42 (s, 4H), 2.29 (s, 1H), 2.19 (s, 3H), 1.92 (d, $J = 1.6$ Hz, 3H), 1.85 (d, $J = 6.8$ Hz, 2H), 1.85–1.74 (m, 3H), 1.68 (dd, $J = 14.5, 7.3$ Hz, 2H), 1.41 – 1.32 (m, 4H), 1.34 – 1.26 (m, 6H), 1.16 (dd, $J = 15.0, 7.8$ Hz, 2H), 0.75 (t, $J = 7.5$ Hz, 3H); ¹³C NMR (100 MHz, CD₃OD) δ 171.2, 167.6, 163.8, 160.1, 156.8, 155.5, 151.9, 147.1, 144.6, 137.9, 135.2, 133.5, 132.7, 128.2, 126.4, 124.4, 120.0, 119.9, 116.8, 116.1, 115.60, 108.7, 62.7, 60.1, 58.0, 55.2, 48.8, 48.7, 48.5, 45.3, 41.4, 31.9, 31.1, 27.4, 27.2, 26.6, 24.3, 20.0, 18.6, 13.5, 13.0, 12.6, 9.8, 7.6; HRMS ESI calculated for $C_{44}H_{57}BF_2N_{10}O_4$ $[M+H]^+$: 839.4704; found 839.4708.

Cell Culture. Hela S3 cells were grown in DMEM medium supplemented with 10% FBS and 1% penicillin/ streptomycin and incubated at 37°C and 5% CO₂.

In vitro kinase assay. Kinase assays for Mps1, PLK1, PLK2, and PLK3 were conducted at Life Technologies. Specifically, inhibition of Mps1 by Mps1-IN-1 and Mps1-IN-BODIPY was measured by LanthaScreen™ Kinase assay (LifeTechnologies; see <http://tools.invitrogen.com/content/SFS/lanthaScreen/PV3792%20TTK%20Assay%20Validation.pdf>) and inhibition of PLK1, PLK2, and PLK3 by BI2536 and BI-BODIPY were measured by

Z'-Lyte™ kinase assay (see https://tools.invitrogen.com/content/sfs/manuals/zlyte_serthr_16_man.pdf).

Mitotic Arrest Assay. HeLa S3 cells were plated at 80% confluence one day prior to the beginning of the experiment. Cells were treated with BI-2536 or BI-BODIPY for 24 hours. Cell lysates were harvested, and lysates were analyzed by Western blot for cyclin B levels using cyclin B1 antibody (1:1000, Bethyl).

Immunofluorescence. HeLa S3 cells used in immunofluorescence experiments were plated on poly-D-Lysine-coated 12-mm coverslips. Cells were arrested at the G1/S transition by 24-hour treatment with thymidine. Cells were released by thymidine washout and after 8 hours cells were treated with BI-BODIPY fluorophore compound (100 nM) with and without competing unlabeled BI2536 parent compound (1 μ M) for 2 hours. This concentration was predetermined to provide the best staining with the lowest background. Higher concentrations of BI-BODIPY resulted in higher background staining and were avoided for this reason as well as to avoid undesired inhibition of the kinase target. Samples were fixed with 4% paraformaldehyde in PBS at room temperature for 20 minutes. Following PBS wash, cells were permeabilized with 0.1% Triton-X in PBS (PBST). Samples were then blocked with 5% BSA in PBST for 30 minutes, incubated with mouse DM1 α anti-tubulin primary antibody (1:2000, Sigma Aldrich) for 1 hour at room temperature, washed with PBST, and incubated with goat anti-mouse AlexaFluor 594 secondary antibody (1:2000, Life Technologies) for an additional 1 hour at room temperature. Coverslips were then washed and stained with PBST containing Hoechst 33342 (1:2000, Life Technologies), washed, and mounted using ProLong Antifade (Life Technologies). Images were analyzed on a Nikon Ti motorized inverted microscope with a Perfect Focus System. Wide field Images were acquired with a cooled CCD camera (Hamamatsu ORCA-R2) and Metamorph software.

References

1. N. Kwiatkowski, N. Jelluma, P. Filippakopoulos, M. Soundararajan, M. S. Manak, M. Kwon, H. G. Choi, T. Sim, Q. L. Deveraux, S. Rottmann, D. Pellman, J. V. Shah, G. J. Kops, S. Knapp and N. S. Gray, *Nat Chem Biol*, 2010, **6**, 359-368.
2. *Germany Pat.*, EP1599478 and WO2003EP01935, 2004.

